Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233141 | 0.82 | CHRM2 (0.37) | HTR6HRH3KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL271868 | 0.82 | HTR6 (0.67) | HTR6HRH3KMT2AHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL18693791 | 0.81 | CHRM2 (0.36) | HTR6HRH3KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL1825076 | 0.80 | HRH3 (0.42) | HRH3KMT2AABCB1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL452359 | 0.80 | HTR6 (0.64) | HTR6HRH3KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL451992 | 0.80 | HTR6 (0.64) | HTR6HRH3KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL943337 | 0.80 | HTR6 (0.64) | HTR6HRH3KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL43171 | 0.80 | HTR6 (0.64) | HTR6HRH3KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL1267270 | 0.80 | HTR6 (0.64) | HTR6HRH3KMT2AHPGDSMN1; SMN2 | |
| Iodomethane SCHEMBL27811080 | 0.78 | HTR6 (0.57) | HTR6HRH3KMT2AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902184-B2 | Piperazinyl pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HRH2, P2RX5, P2RX3 | HTR6 151/4885HRH3 8/4885KMT2A 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.